Back to search
FDAFDA · Food and drugs·Recall number F-1523-2013

XYMOGEN EP Exclusive Patented Dietary Supplement Artriphen Clinically Tested to Support Healthy Joint Function, 90 and 180 capsule bottles

Published June 19, 2013 · Recall initiated: May 1, 2013

Summary

FDA records food Class I recall F-1523-2013, published June 19, 2013 and initiated May 1, 2013. Recalling firm: Atlantic Pro Nutrients, Inc. dba XYMOGEN; Status: Terminated; Reported quantity: 16,268 units; Lot: All SKUs. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Undeclared Soy and Milk on the label.

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Atlantic Pro Nutrients, Inc. dba XYMOGEN
Distributor
AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, IA, IL IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, NC, NJ, NM, NY, OH, OK, PA, RI, SC, TN, TX, UT, VA, WA, WI, WV, WY, District of Columbia and Hawaii
Lot
All SKUs
Risk classification
Class I
Area (FDA)
food
Country
United States

Related recalls

Questions about this recall

Was XYMOGEN EP Exclusive Patented Dietary Supplement Artriphen Clinically Tested to Support Healthy Joint Function, 90 and 180 capsule bottles recalled?

Yes. FDA published recall F-1523-2013 on June 19, 2013. Reported hazard: Undeclared Soy and Milk on the label.

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit